Taysha Gene Therapies’ (TSHA) Market Outperform Rating Reiterated at JMP Securities

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “market outperform” rating reiterated by investment analysts at JMP Securities in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $5.00 target price on the stock. JMP Securities’ price target points to a potential upside of 174.73% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Needham & Company LLC restated a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Monday. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock opened at $1.82 on Monday. Taysha Gene Therapies has a fifty-two week low of $1.05 and a fifty-two week high of $4.32. The stock’s 50 day simple moving average is $1.56 and its two-hundred day simple moving average is $1.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The stock has a market cap of $373.20 million, a price-to-earnings ratio of 2.89 and a beta of 0.96.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. The company had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. As a group, analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Institutional Trading of Taysha Gene Therapies

Institutional investors and hedge funds have recently modified their holdings of the business. Hsbc Holdings PLC lifted its holdings in shares of Taysha Gene Therapies by 65.6% during the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock valued at $36,000 after purchasing an additional 8,076 shares in the last quarter. Virtus ETF Advisers LLC boosted its holdings in shares of Taysha Gene Therapies by 43.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company’s stock valued at $55,000 after acquiring an additional 9,494 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Taysha Gene Therapies by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock worth $6,182,000 after acquiring an additional 9,591 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Taysha Gene Therapies by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock valued at $820,000 after purchasing an additional 11,390 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in Taysha Gene Therapies by 7.0% during the first quarter. Rhumbline Advisers now owns 205,462 shares of the company’s stock valued at $286,000 after purchasing an additional 13,383 shares during the period. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.